The Federal Trade Commission on Tuesday sued to block Amgen ‘s $27.8 billion acquisition of Horizon Therapeutics laying out a rationale that, if upheld by federal courts, could broadly undermine the biotechnology ecosystem.
This story from barrons.com was posted on 2023-05-17 by @glowbug.